Deliver your company news, directly to investors, where they look for it.
Today more than ever, you must reach investors with relevant and concise information.
Institutional Investors
- ABN Newswire is globally accredited to the top tier of financial news via Bloomberg, Thomson Reuters, Dow Jones Factiva and more. We deliver text and video directly to institutional desktops.
- Read More
Retail Investors
- Reaching retail investors via equity websites, search engines and financial blogs is no longer out of reach with ABN Newswire's unique distribution model. Your news is easily integrated on any website.
- Read More
Social Investors
- Instant broadcasting of your news, images and video through LinkedIn, Facebook and Twitter. Reduce your time and effort posting on Social Media, we do it for you.
- Read More
Professional Audience
Companies Represented
Pages Served
Languages
News Distribution
rapidVideo Production
+live webcastingInvestment Shows
investorium.tvCEO Interviews
+corporate videoHosted AGMs
+webcastIR Websites
+multiple languagesSocial Media
+postingWhy Choose Us
With years of cutting edge software development, ABN Newswire has integrated with every major news provider and social media in multiple languages...
ABN Newswire monitors your newsflow and knows instantly when you make a company announcement. Our alert system tells you we are already working on distributing your news...
Our reporting tells you how many are reading your news, referrals to your website and your most read announcements by week, month and year, with interactive stock price and news reads chart data...
Recent News
- 11Sep2024
Big Wave Grand Prix, the event that revolutionizes giant wave surfing
The Big Wave Grand Prix (BWGP) is set to revolutionize the world of big wave surfing with the launch of its innovative interactive platform during the 2024/25 season.
Read More
- 11Sep2024
First Participant Dosed in Phase 1 Clinical Trial of Gamma-PN in Older Adults
GPN Vaccines Ltd is pleased to announce that the first participant has been dosed in its Phase 1 clinical trial of Gamma-PN vaccine in older adults. The Phase 1 clinical trial will assess the safety, tolerability and immunogenicity of Gamma-PN.
Read More